Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening

[1] Cuzick J(2008)Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries Vaccine 26 K29-K41

[2] Arbyn M(2003)Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 518-527

[3] Sankaranarayanan R(2009)Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States J Natl Cancer Inst 101 475-487

[4] Tsu V(2005)The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice J Natl Cancer Inst 97 1072-1079

[5] Ronco G(2011)Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study Lancet Oncol 12 880-890

[6] Mayrand MH(2007)A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion J Infect Dis 195 1582-1589

[7] Munoz N(2012)American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer CA Cancer J Clin 62 147-172

[8] Bosch FX(2013)Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists Am J Prev Med 45 175-181

[9] de Sanjose S(2010)Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening Gynecol Oncol 119 237-242

[10] Herrero R(2009)Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions Br J Cancer 101 511-517

[1] Cuzick J(2008)Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries Vaccine 26 K29-K41

[2] Arbyn M(2003)Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 518-527

[3] Sankaranarayanan R(2009)Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States J Natl Cancer Inst 101 475-487

[4] Tsu V(2005)The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice J Natl Cancer Inst 97 1072-1079

[5] Ronco G(2011)Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study Lancet Oncol 12 880-890

[6] Mayrand MH(2007)A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion J Infect Dis 195 1582-1589

[7] Munoz N(2012)American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer CA Cancer J Clin 62 147-172

[8] Bosch FX(2013)Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists Am J Prev Med 45 175-181

[9] de Sanjose S(2010)Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening Gynecol Oncol 119 237-242

[10] Herrero R(2009)Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions Br J Cancer 101 511-517